RJ Hamster
Central banks are lying to you about gold
| Jerome Powell says gold is not money. The Fed says inflation is under control. They say the dollar is strong. Now look at what they DO. Central banks bought more gold last year than any time since 1967. China dumped $100 billion in U.S. debt. Then bought gold. Poland. Hungary. Singapore. Turkey. All loading up. This isn’t a trend. This is a panic. Why now? In 2022, we froze Russia’s money. We showed the world: ‘Play by our rules or we take your cash.’ China saw that. Saudi Arabia saw that. Now they want out. There’s only one asset no one can freeze. Gold. The smart money is moving. Are you? I just put out an urgent report on the one stock I think could surge 1,000% as this panic grows. >> Get the name and ticker here << The Buck Stops Here, Dylan Jovine Today’s Bonus Story Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 Authored by Nathan Reiff. First Published: 2/2/2026. Key Points Corvus Pharmaceuticals has nearly tripled in value this year amid optimism that its atopic dermatitis drug candidate will continue to deliver strong trial results. Despite legal and other hurdles, New Era Energy & Digital recently noted a key achievement in its path toward providing data center capacity. USA Rare Earth has received around $1.6 billion in federal funding as it seeks to provide a domestic alternative to foreign rare earth minerals. Nearly one month into 2026, the S&P 500 has been sluggish, up just over 1% after multiple dips in January. That middling performance masks the fact that several individual companies have had a supercharged start to the year, dramatically outperforming the market benchmark. Investors seeking to capitalize on rising momentum might consider companies such as Corvus Pharmaceuticals Inc. (NASDAQ: CRVS), New Era Energy & Digital Inc. (NASDAQ: NUAI), and USA Rare Earth (NASDAQ: USAR), each of which has returned at least 56% year-to-date (YTD). Analysts Stay Bullish on Corvus With 50%+ Upside Targets What a Roth Conversion Makes Permanent (Ad) Firing Your Financial Advisor: The 5 Major Red Flags Many investors miss these warning signs. Learn five red flags that trigger advisor reviews. As a clinical-stage biopharma company, Corvus is in a sector prone to rapid, sizable stock swings. A recent catalyst for the shares has been positive data from its drug candidate soquelitinib, being developed to treat atopic dermatitis and other conditions. In mid-January, Corvus reported promising Phase 1 results, including a reported 72% reduction in eczema severity among trial patients. That news helped Corvus shares surge roughly 188% YTD. A Phase 2 trial is planned for early in the year and could push the stock higher. To fund the upcoming trial, Corvus launched a $150-million equity offering to extend its cash runway, though that move risks diluting existing shareholders. The financing is important because Corvus ended the third quarter of 2025 with only $67 million in cash. The addressable market for atopic dermatitis is sizable, and analysts remain optimistic. Six of seven coverages rate CRVS a Buy, and the consensus price target implies roughly 51% upside even after the recent rally. New Era’s Data Center Pivot Makes Big Strides, Though Legal and Other Risks Remain New Era & Digital is one of the more polarizing names in the energy exploration and production space. Shares of NUAI are up more than 114% YTD after the company announced a January partnership with Primary Digital Infrastructure to co-develop as much as a gigawatt of hyperscale data center capacity in Texas. Earlier in the month, New Era closed the acquisition of a 50% ownership interest in Texas Critical Data Centers, further positioning the company for a pivot into the high-demand data center market. Those moves suggest New Era could succeed in its reorganization, but risks remain. The Rosen Law Firm has announced plans to investigate allegations of “materially misleading business information.” With a market value just under $400 million, New Era is a small, high-risk company. Investors willing to accept those risks may be rewarded if the rally continues. USA Rare Earth Looks to Fill a Significant Supply Chain Need With Government Support Rare-earth minerals are critical for many modern technologies, and supply-chain and international trade concerns threaten U.S. access. USA Rare Earth aims to provide a domestic alternative. The company has been buoyed by a $1.6-billion investment from the federal government and additional private investments in recent weeks, on top of a strong cash position reported with its latest earnings. The firm’s rare-earth and magnet production capacity is expanding rapidly thanks to key operations in Texas, and revenues are expected to grow sharply. However, USA Rare Earth remains an early-stage company without a proven track record of profitability, which could deter some investors. Still, its 56% YTD return and a strongly optimistic analyst-rating profile suggest significant potential upside. This email content is a sponsored message for Behind the Markets, a third-party advertiser of MarketBeat. Why did I receive this email?. If you have questions about your account, please feel free to contact MarketBeat’s U.S. based support team at contact@marketbeat.com. If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here. © 2006-2026 MarketBeat Media, LLC. 345 N Reid Pl. #620, Sioux Falls, South Dakota 57103. USA.. Further Reading: 5 Best Stocks Under $5 to Buy Now (Click to Opt-In) |
